Business context and reporting period
DexCom, Inc. develops and sells continuous glucose monitoring systems for diabetes management. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2022. Comparatives reflect the company’s retrospective adoption of convertible-debt accounting guidance and four-for-one stock split.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $696.2m | $595.1m | $1,325.0m | $1,100.1m |
| Gross profit / margin | $449.5m / 64.6% | $417.1m / 70.1% | $847.6m / 64.0% | $761.0m / 69.2% |
| Operating income / margin | $77.0m / 11% | $101.0m / 17% | $118.3m / 9% | $146.9m / 13% |
| Net income | $50.9m | $78.4m | $148.2m | $134.9m |
| Diluted EPS | $0.12 | $0.19 | $0.36 | $0.33 |
- Q2 revenue rose 17%; six-month revenue rose 20%. Management attributed growth mainly to higher disposable sensor volume and worldwide customer growth. Sensors and other products were 86% of revenue in Q2, versus 83% a year earlier.
- Q2 operating cash flow was $172.8m, up 181% year over year; six-month operating cash flow was $243.8m versus $89.4m. Six-month capital expenditures were $193.1m.
- At June 30, cash and cash equivalents were $735.4m and short-term marketable securities were $2,019.4m, totaling about $2.75bn. Current assets were $3,808.7m and current liabilities $807.0m; reported working-capital and quick ratios were 4.72 and 4.11.
- Convertible-note principal totaled $1,982.3m ($774.8m due 2023 and $1,207.5m due 2025); carrying value was $1,967.3m. The $200m revolving facility had no borrowings and $192.7m available after letters of credit. The company reported compliance with its covenants.
Material changes versus prior period
- Revenue growth did not translate into higher operating profit: Q2 operating income fell 24% and net income fell 35%. Gross margin declined to 64.6% from 70.1%, primarily due to pricing and channel mix.
- For the six-month period, gross margin fell to 64.0% from 69.2%, also reflecting higher excess and obsolescence reserves as older-generation CGMs were phased out. SG&A rose 25% for the half, including higher marketing, compensation, litigation, depreciation and travel costs.
- Six-month net income increased 10% despite lower operating income, aided by a $36.8m income-tax benefit versus $3.5m expense a year earlier. The benefit primarily reflected discrete excess tax benefits from share-based compensation and the Verily milestone, plus R&D tax credits.
- Cash and cash equivalents declined from $1,052.6m at year-end, while marketable securities increased; combined cash and short-term securities rose about $23.6m to $2.75bn.
Outlook, risks and unusual items
- No specific revenue or earnings guidance is provided in the filing. Management expects positive operating cash inflows and said cash, investments, projected operating cash flows and credit availability should cover anticipated needs for at least 12 months.
- Management expects significant capital spending to build out the Malaysia manufacturing facility and expand capacity in Mesa, Arizona. It estimated 2022 full-year effective tax rate from normal recurring operations at 31.4%.
- Key risks include COVID-19-related supply-chain and operational disruption, inflation and rising costs, dependence on certain single-source suppliers, manufacturing scale-up and product quality, reimbursement and pricing pressure, competition, and delays in regulatory approval or commercialization of next-generation CGM products, particularly G7. International growth also increases currency and execution risks.
- DexCom and Abbott entities have brought patent-related actions against each other in multiple jurisdictions; management intends to pursue its claims and defenses and does not believe current proceedings are expected to have a material adverse effect, while noting outcomes cannot be assured.
- On July 26, 2022, after quarter-end, the board authorized a share repurchase program of up to $700m through June 30, 2023. It is discretionary and does not require repurchases.
- Other notable items: DexCom issued about 2.9m shares for a Verily regulatory milestone in Q1; possible additional sales-based milestone shares are not considered probable and have not been recognized. The 2023 notes were convertible at holders’ option during Q3 2022 under the stated stock-price condition.
Important facts for investors to verify
- Whether sensor volume growth can continue while pricing and channel mix pressure margins.
- Progress, regulatory timing and manufacturing readiness for G7 and the Malaysia and Mesa capacity expansions.
- Cash conversion and capital spending trends, including the effect of the announced buyback on liquidity and share count.
- Developments in Abbott patent litigation, 2023-note conversions, and potential dilution from notes, warrants and Verily milestones.
- Whether reimbursement access, supply-chain conditions, inflation and the 31.4% recurring tax-rate estimate evolve as management expects.